Recognition of the consistent molecular and genetic alteration of BCR-ABL in CML patients' leukemic cells led to the development of TKIs with selectivity for the BCR-ABL kinase [4, 89, 90]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.